These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 14512190)

  • 1. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
    Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
    Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
    Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
    Keller SM; Vangel MG; Wagner H; Schiller JH; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
    J Thorac Cardiovasc Surg; 2004 Jul; 128(1):130-7. PubMed ID: 15224032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations.
    Okada M; Tsubota N; Yoshimura M; Miyamoto Y; Matsuoka H
    Chest; 2000 Jul; 118(1):123-8. PubMed ID: 10893369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
    Liu K; Chen HL; You QS; Huang JF; Wang H
    Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IIIB-T4 non-small cell lung cancer: indications and results of surgical treatment.
    Lucchi M; Viti A; Melfi F; Ambrogi M; Givigliano F; Dini P; Mussi A
    J Cardiovasc Surg (Torino); 2007 Jun; 48(3):369-74. PubMed ID: 17505443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer.
    Yuan C; Tao X; Zheng D; Pan Y; Ye T; Hu H; Xiang J; Zhang Y; Chen H; Sun Y
    J Surg Oncol; 2019 Mar; 119(3):379-387. PubMed ID: 30536966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lung cancer: is surgery an option for persisting N2 after induction therapy?].
    Haager B; Osei-Agyemang T; Passlick B; Wiesemann S
    Zentralbl Chir; 2015 Feb; 140(1):99-103. PubMed ID: 25076164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].
    Yu DP; Bai LQ; Xu SF; Han M; Wang ZT
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):465-8. PubMed ID: 19950561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
    Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
    Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
    Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival following resection of clinically occult N2 non small cell lung cancer.
    Dalton R; Keller S
    J Cardiovasc Surg (Torino); 1994 Dec; 35(6 Suppl 1):13-7. PubMed ID: 7775526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.